Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Yes, the P2/P3 trial was indeed successful. Was it big enough? IDK, maybe. FWIW, just because Dr. Jin has an opinion doesn't mean Anavex will act on it. He is a statistician not a regulatory affairs specialist - although doubtless he has the experience to qualify as more expert that many regulatory people. It is the C suite - CM in particular - who will decide whether to run bigger, faster, and more trials. So far, they have failed 3x to run trials that are big and fast enough (the 2 Rett trials were undersized and the AD trial was undersized, too.)

To be clear, if Dr. Jin thought another P3 was needed then it is pretty unlikely that would matter to CM. Am sure CM values Dr. Jin's expertise but CM is fundamentally opposed to spending money to de-risk the business so he is not going to act on this kind of advice.